32 results about "Mesodermal cell" patented technology

The present invention provides compositions and methods for the production of differentiated mammalian cells. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a feeder layer or under feeder-free conditions in cell culture and further contacting the cells with an inhibitor of the PI3-kinase pathway for the generation of differentiated mammalian cells from pluripotent mammalian stem cells. Preferably, the differentiated cell is selected from the group consisting of a mesendodermal cell, a mesodermal cell, and an endodermal cell.

The present invention relates generally to the generation of cells of mesodermal lineage. More particularly, the present invention contemplates a method for the preparation of differentiated or partially differentiated mesodermal cells and their use in tissue repair, regeneration and/or augmentation therapy. The identification and generation of the mesodermal cells further provides a source of transcriptome or proteome data to assess the expression profile of genes associated with the maintenance of mesodermal cells as well as their differentiation, proliferation, expansion and/or renewal potential.

The present invention relates to placenta tissue-derived multipotent stem cells and cell therapeutic agents containing the same. More specifically, to a method for producing placenta stem cells having the following characteristics, the method comprising culturing amnion, chorion, decidua or placenta tissue in a medium containing collagenase and bFGF and collecting the cultured cells: (a) showing a positive immunological response to CD29, CD44, CD73, CD90 and CD105, and showing a negative immunological response to CD31, CD34, CD45 and HLA-DR; (b) showing a positive immunological response to Oct4 and SSEA4; (c) growing attached to plastic, showing a round-shaped or spindle-shaped morphology, and forming spheres in an SFM medium so as to be able to be maintained in an undifferentiated state for a long period of time; and (d) having the ability to differentiate into mesoderm-, endoderm- and ectoderm-derived cells. Also the present invention relates to placenta stem cells obtained using the production method. The inventive multipotent stem cells have the ability to differentiate into muscle cells, vascular endothelial cells, osteogenic cells, nerve cells, satellite cells, fat cells, cartilage-forming cells, osteogenic cells, or insuline-secreting pancreatic β-cells, and thus are effective for the treatment of muscular diseases, osteoporosis, osteoarthritis, nervous diseases, diabetes and the like, and are useful for the formation of breast tissue.

The invention provides a preparation method of epicardial cells from multipotent stem cells. The method comprises the following steps: (1) by activating WNT signal pathways, inducing the multipotent stem cells to be differentiated into mesodermal cells; 2) by inhibiting the WNT signal pathways, converting the mesodermal cells obtained in the step 1) into myocardial precursor cells; 3) by activating retinoic acid signal pathways and the WNT signal pathways, converting the myocardial precursor cells obtained in the step 2) into anterior epicardial cells; and 4) preparing the epicardial cells from the anterior epicardial cells obtained in the step 3). The invention further relates to a method for preparing vascular smooth muscle cells and cardiac fibroblasts from the multipotent stem cells, the epicardial cells, the vascular smooth muscle cells and the cardiac fibroblasts prepared with the method, and application of the epicardial cells, the vascular smooth muscle cells and the cardiac fibroblasts.

The invention provides a method of using multipotent stem cells to prepare epicardial cells, comprising: 1) inducing multipotent stem cells to differentiate into mesodermal cells by activating a WNT signal pathway; 2) converting the mesodermal cells in step 1) into myocardial precursor cells by inhibiting the WNT signal pathway; 3) converting the myocardial precursor cells in step 2) into preliminary epicardial cells by activating a fibroblast growth factor signal pathway and the WNT signal pathway; preparing pericardial cells with the preliminary epicardial cells of step 3). The invention also relates to: a method of using multipotent stem cells to prepare vascular smooth muscle cells and cardiac fibroblasts; epicardial cells, vascular smooth muscle cells and cardiac fibroblasts all of which are prepared through the above method; and their application.

This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine.

The present invention provides a culture method for culturing, in recesses (10), a population including two or more cells including a cell derived from a stem cell and a mesenchymal cell. The cell derived from a stem cell is a cell obtained by differentiating a stem cell in vitro. The cell is a cell of one or more types selected from the group consisting of an endodermal cell, an ectodermal cell, and a mesodermal cell. The population is cultured in the recesses (10) together with a vascular cell or a secretor factor. Each recess (10) includes a space in which cells are movable. When a volume of the space is represented by V mm³ and the number of mesenchymal cells seeded in the space is represented by N, V is 400 or less and N/V is in a range from 35 to 3000.

The invention discloses a pharmaceutical composition for treating female reproductive track infection and a preparation method thereof. The pharmaceutical composition comprises polylysine microspheres, fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii, Chinese usnea, poloxamer F127 and poloxamer F68, wherein the content of the polylysine microspheres is 0.01-0.05% by mass percent; the total content of fructus ligustri lucidi, radix sophorae flavescentis, fructus cnidii and Chinese usnea is 1-7%; the ratio of fructus ligustri lucidi to radix sophorae flavescentis to fructus cnidii to Chinese usnea is 1:1:2:1; the content of poloxamer F12 is 17-30%; the content of F68 is 0-20%; and the rest is water. After the polylysine microspheres and the traditional Chinese medicine composition are compounded, vaginal wound healing is effectively promoted. The pharmaceutical composition has a repair and regeneration promotion function on cells of a mesoderm and an ectoderm, and canpromote regeneration of blood capillaries, improve the local blood circulation and quicken wound healing. Polylysine becomes amino acid after being decomposed and can serve as a nutrient substance tobe absorbed.

This invention provides unique members of the Hect family of ubiquitin ligases that specifically target BMP and TGF beta /activin pathway-specific Smads. The novel ligases have been named Smurf1 and Smurf2. They directly interact with Smads1 and 5 and Smad7, respectively, and regulate the ubiquitination, turnover and activity of Smads and other proteins of these pathways. Smurf1 interferes with biological responses to BMP, but not activin signalling. In amphibian embryos Smurf1 inhibits endogenous BMP signals, resulting in altered pattern formation and cell fate specification in the mesoderm and ectoderm. The present invention provides a unique regulatory link between the ubiquitination pathway and the control of cell fate determination by the TGF beta superfamily during embryonic development. Thus, Smurf1 is a negative regulator of Smad1 signal transduction, by targeting Smad1, Smurf1 blocks BMP signalling. In mammalian cells, Smurf2 suppresses TGF beta signalling, and in Xenopus, blocks formation of dorsal mesoderm and causes anterior truncation of the embryos. Smurf2 forms a stable complex with Smad7, which induces degradation and downregulation of TGF beta /activin signalling.

The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues.

The present invention relates to a method of generating neural stem cells from mesodermal cells. The invention further provides a cell population which has neural stem cell-like characteristics. The neural stem cells prepared according to the invention are useful in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The invention relates to a method for inducing directional endothelial differentiation of human pluripotent stem cells. The method specifically comprises the following steps: 1, when the human pluripotent stem cells reach 80% fusion or above, induced differentiation is performed on digested stem cells by using a differential medium containing 10-50ng/ml of WNT3a; 2, induced differentiation is further performed on the cells by using a differentiation medium containing 10-50ng/ml of WNT3a and 10-30ng/ml of BMP2; 3, induced differentiation is further performed on the induced differentiated cells in the step 2 by using a differential medium containing 10-30ng/ml of BMP2 into mesodermal cells; and 4, induced differentiation is further performed on the cells by using a culture medium containing 10-15ng/ml of FGF8 into endothelial cells. According to the invention, by improving the mediums and related cell factors, the experimental scheme can have higher endothelial induction efficiency.

An object of the present invention is to provide a method for differentiating mesodermal cells into mesothelium cells. The present invention provides a method for producing mesothelial cells, including a first culturing step of culturing mesodermal cells in a medium containing basic fibroblast growth factor (bFGF) and oncostatin M.